Protalix BioTherapeutics, Inc. (PLX) Financials

The erratic revenue trajectory suggests that Protalix remains heavily dependent on the timing of specific contract deliveries rather than a steady, predictable patient-demand curve. Investors should monitor whether the recent revenue spike in 2026Q1 represents a sustainable shift or merely a temporary recognition of deferred milestones.

The wide variance in gross margins indicates that the company has not yet achieved the economies of scale necessary to stabilize its production costs. This volatility suggests that the underlying manufacturing process remains sensitive to volume fluctuations, which may continue to pressure profitability until commercial adoption of Elfabrio reaches a more consistent threshold.

The lack of a clear, linear relationship between gross profit and operating income suggests that fixed overhead costs remain a significant burden on the bottom line. Future performance will likely depend on whether management can maintain SG&A discipline while scaling commercial operations, as current figures indicate high sensitivity to operational expenses.